Monitor FDA acceptance of the BLA (expected within 60 days) and the priority review decision. The upcoming four-year data presentation before end of Q3 2026 could further de-risk the regulatory path. Any FDA rejection or delay would be a significant negative catalyst.
Price Chart
Executive Summary
uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, along with a parallel Marketing Authorisation Application (MAA) to the UK MHRA. The submissions are supported by three-year Phase I/II data showing slowed disease progression, and the company has requested priority review, which could shorten the FDA review cycle to six months. This is a major regulatory milestone for a first-in-class therapy addressing a large unmet need, though approval is not guaranteed and the stock has historically underperformed on high-impact events.
Key Facts
- BLA submitted to FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease
- MAA submitted to UK MHRA for the same therapy
- Priority review requested for the BLA; if granted, FDA review cycle would be six months after the 60-day filing review period
- Submissions supported by three-year data from Phase I/II study showing slowing of disease progression vs. propensity score-matched external control
- Company plans to present four-year data analysis from ongoing Phase I/II studies before end of current third quarter
- Ifezuntirgene inilparvovec holds FDA Breakthrough Therapy and RMAT designations, as well as Fast Track designation
Financial Impact
No financial figures disclosed; potential multi-billion-dollar market opportunity if approved for ~75,000 patients in U.S., EU, and UK with no currently approved disease-modifying therapies
Risk Factors
- FDA may not accept the BLA for filing or may deny priority review
- Phase I/II data may be deemed insufficient for accelerated approval; confirmatory study may be required
- Regulatory decisions in the UK (MHRA) are independent and may differ from FDA
- Historical stock performance on high-impact events for QURE has been negative on average (40% win rate at T+20)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-104463 |
| Document: qure-20260902xex99d1.htm | 0001104659-26-104463 |
| Document: 0001104659-26-104463-index-headers.html | 0001104659-26-104463 |
| Document: 0001104659-26-104463-index.html | 0001104659-26-104463 |
| Document: 0001104659-26-104463.txt | 0001104659-26-104463 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access